Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. clinic celiacshield trial
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Clinic Celiacshield Trial Articles & Analysis: Older

1,554 news found

Ace Therapeutics Launches Gene Therapy Development Services to Unleash Glaucoma Drug Research

Ace Therapeutics Launches Gene Therapy Development Services to Unleash Glaucoma Drug Research

Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease. Glaucoma is a group of eye conditions that damage the optic nerve, often ...

ByAce Therapeutics


SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...

BySOPHiA Genetics


Biopharma PEG Expands GMP Production of Lipids and PEGs to Meet Growing Demand for Lipid Nanoparticles

Biopharma PEG Expands GMP Production of Lipids and PEGs to Meet Growing Demand for Lipid Nanoparticles

Biopharma PEG, a key provider of premium polyethylene glycol (PEG) derivatives, is thrilled to announce a substantial expansion of its large-scale Good Manufacturing Practice (GMP) production capabilities. This strategic move is aimed at addressing the rising global demand for Lipid Nanoparticles (LNPs), which are vital for nucleic acid drug delivery, especially in mRNA-based therapies and ...

ByBiopharma PEG Scientific Inc


SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from ...

BySOPHiA Genetics


Ace Therapeutics Unveils Model Development Services to Power Up Psychiatric Drug R&D

Ace Therapeutics Unveils Model Development Services to Power Up Psychiatric Drug R&D

Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development. Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat ...

ByAce Therapeutics


SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to ...

BySOPHiA Genetics


Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Creative Enzymes, a leading provider of high-quality enzymes and biochemicals, is proud to announce the addition of Semaglutide to its comprehensive product portfolio. This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide ...

ByCreative Enzymes


CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials

CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials

CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...

ByCanaQuest Medical Corp.


New Insights into Migraine Treatment: CGRP Levels After Monoclonal Antibody Cessation

New Insights into Migraine Treatment: CGRP Levels After Monoclonal Antibody Cessation

Researchers have made some fascinating discoveries about the treatment of migraine. Calcitonin gene-related peptide (CGRP) has long been associated with the development of migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway, including erenumab, galcanezumab and fremanezumab, have shown promise in clinical trials and real-life studies. Initially, the European Headache Federation ...

ByBertin Technologies


Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of ...

ByOncoVITA


STEMart Announces Pilot Production Services for Medical Devices

STEMart Announces Pilot Production Services for Medical Devices

STEMart, a US-based provider of comprehensive services for all phases of medical device development, is proud to announce the launch of its new Pilot Production Services for the medical device industry. These services allow manufacturers to test and refine their products prior to full-scale production, streamlining the development process of new medical devices and minimizing risk to save time ...

BySTEMart


Biopharma Stock News Bite - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) Spikes on News Potential Treatment for Alcohol Use Disorder

Biopharma Stock News Bite - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) Spikes on News Potential Treatment for Alcohol Use Disorder

Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. The stock is trading at $2.0050, up $0.8750, gaining +77.0925% on volume of over 8o ...

ByInvestorideas.com


Biotech Stock News Bite - Longeveron Inc. (NASDAQ: LGVN) Stock Soars on Clinical Pipeline and 2024 Key Priorities and Goals

Biotech Stock News Bite - Longeveron Inc. (NASDAQ: LGVN) Stock Soars on Clinical Pipeline and 2024 Key Priorities and Goals

Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. The stock had a morning high of $5.47 on volume of over 36 Million/. The Company's CEO, ...

ByInvestorideas.com


Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research

Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...

ByCreative Diagnostics


CEPI’s $3.6B Initiative with ExcellGene: Single Molecule for Global Defense in COVID Trials

CEPI’s $3.6B Initiative with ExcellGene: Single Molecule for Global Defense in COVID Trials

A delegation of CEPI (Coalition of Epidemic Preparedness and Innovation) was received by ExcellGene SA, the biotech service company in Monthey, on December 4th for a two day scientific discussion event. The meeting was held together with delegations from India (Bharat Biotech, Hyderabad, India) and Australia (University of Sydney, Prof. Jamie Triccas) which, together with ExcellGene, ...

ByExcellGene SA


Vitalograph celebrates 60th anniversary

Vitalograph celebrates 60th anniversary

Founded in 1963, in Maids Moreton, Vitalograph’s mission has remained unwavering over the past six decades – to improve the lives of people living with lung conditions through the development and manufacture of respiratory diagnostic solutions. As experts in pulmonary function, they also provide clinical drug trial services that enable the development of life-changing respiratory ...

ByVitalograph Inc


NHL Alumni Association partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in former NHL Players

NHL Alumni Association partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in former NHL Players

NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...

ByCanaQuest Medical Corp.


CANAQUEST Announces Award of European Cannabinoid Patent

CANAQUEST Announces Award of European Cannabinoid Patent

We believe we can provide a safer alternative to other THC products providing the benefits without the negative psychiatric side effects. Pre-clinical trials have demonstrated the reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity, and gene vulnerability. CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a ...

ByCanaQuest Medical Corp.


Vitalograph expands Clinical Trial services portfolio with centralized DLCO, decentralized spirometry, and integrated oscillometry solutions.

Vitalograph expands Clinical Trial services portfolio with centralized DLCO, decentralized spirometry, and integrated oscillometry solutions.

With more than 60 years’ expertise in respiratory diagnostics, Vitalograph is the only company in the world specialized in delivering clinical trial services exclusively for pulmonary function-focused studies. Speaking about the recent additions to their portfolio of services, Richard James, Executive Vice President and Chief Operating Officer of Vitalograph Clinical Trials says: ...

ByVitalograph Inc


Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...

ByTris Pharma, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT